Omicron News and Research

RSS

RSV and kids: What you need to know

An overview on the prevalence, symptoms, and management of RSV in children.

2 Nov 2022

What is the role of cyclophilin-A in alleviating SARS-CoV-2 infections?

A new study aimed to analyze the molecular interactions between the hCypA protein and the SARS-CoV-2 variants to determine the impact of variants on the blocking and binding potential of the hCypA–S protein complex with the ACE2 receptor.

2 Nov 2022

Effectiveness of prior infection in preventing reinfection with SARS-CoV-2 Omicron BA.2.75 sublineage

Researchers used a test-negative, case-control study design to estimate the effectiveness of prior infection in preventing reinfection with Omicron BA.2.75.2 subvariant in the Qatar population.

2 Nov 2022

How does imprinted SARS-CoV-2 humoral immunity drive convergent Omicron evolution?

Researchers examined how imprinted SARS-CoV-2 humoral immunity drives convergent evolution in continuously emerging Omicron subvariants.

2 Nov 2022

Exploring trends in SARS-CoV-2 RNA concentrations in wastewater

In a new study, researchers characterized trends of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA levels in wastewater.

1 Nov 2022

Exploring viral loads of SARS-CoV-2 Omicron BA.5 and BA.2 sublineages

In a new study, researchers compared the viral loads of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron BA.5 and BA.2 sublineages.

1 Nov 2022

WHO’s TAG-VE group present the most recent evidence on Omicron sublineages BQ.1 and XBB

WHO’s TAG-VE group presented the most recent evidence on Omicron evolution and genetic diversity.

1 Nov 2022

SARS-CoV-2 Omicron BA.2 less severe than Delta and original Omicron

Researchers estimate the severity of infection with the SARS-CoV-2 Omicron BA.2 subvariant as compared to that caused by the Delta and Omicron variants.

31 Oct 2022

New research suggests booster dose of Novavax NVX-CoV2373 vaccine is effective against SARS-CoV-2 Omicron subvariants

A new study evaluated the neutralizing antibody titers against the SARS-CoV-2 Omicron variant and its sub-lineages after two and three doses of the Novavax protein nanoparticle vaccine NVX-CoV2373.

31 Oct 2022

Italian study evaluates COVID-19 reinfection risk among previously infected and vaccinated individuals

Researchers from Italy investigated the risk of SARS-CoV-2 reinfection and hospitalization among individuals with vaccinations and previous SARS-CoV-2 infections.

31 Oct 2022

Psychosocial impact on pandemic workers in Shanghai during Omicron wave lockdown

In a recent study posted to the medRxiv* server, researchers assessed the well-being of all workers involved in coronavirus disease 2019 (COVID-19) testing between April and June 2022, i.e., during the Omicron wave lockdown in Shanghai, China.

30 Oct 2022

An estimated 15% of U.S. adults infected with SARS-CoV-2 have long-COVID

In a recent study published in the journal JAMA Network Open, researchers in the United States estimated the sociodemographic factors associated with and prevalence of post-acute coronavirus disease 2019 (COVID-19) symptom sequelae (PASC) or long COVID (LCOVID).

30 Oct 2022

New insights on antibody response against SARS-CoV-2 Omiron sublineages

Knowing how well vaccination against one SARS-CoV-2 strain (with or without previous infection) counteracts infection with a different strain is a critical research question.

28 Oct 2022

First anti-SARS Cov2 monoclonal antibody candidate of SpikImm demonstrates excellent tolerance

SPK001, the first anti-SARS Cov2 monoclonal antibody candidate of SpikImm, a French biotechnology company founded by Truffle Capital, originally discovered by the Institut Pasteur's Human Immunology Laboratory, directed by Dr. Hugo Mouquet (Inserm Joint Research Unit), has been tested on three initial cohorts of healthy volunteers, and has demonstrated excellent tolerance, in the context of the Phase 1 clinical study, recently labeled as a "national priority" by CAPNET (National Steering Committee for Therapeutic Trials and other Research on Covid-19).

28 Oct 2022

Booster vaccination offered additional protection to residents and staff of California state prisons against SARS-CoV-2 Omicron

Researchers evaluated to what extent prior infection and vaccination protected the residents and staff of the United States California state prison system from breakthrough infection by SARS-CoV-2 Omicron sub-variant B.1.1.529.

28 Oct 2022

Study refutes the nicotinic hypothesis of SARS-CoV-2 infection mechanism

A new study confirmed that the SARS-CoV-2 spike protein does not bind to human AChR’s orthosteric sites, nor does it compete with ACh, choline, or nicotine.

28 Oct 2022

Scientists computationally restore the potency of an antibody against SARS-CoV-2 Omicron subvariants

A team of researchers from the United States computationally modified the COV2-2130 monoclonal antibody to restore its neutralizing ability against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvariants, while retaining efficacy against the Delta and wild-type strains.

27 Oct 2022

Combination of multi-specificity and antibody avidity enhances protection against SARS-CoV-2

In a recent study posted to the bioRxiv* preprint server, an international team of researchers leveraged the human light chain apoferritin protomer-derived MULTI-specific, multi-Affinity antibody (Multabody, MB) platform for the generation of broad and potent SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2)-neutralizing antibodies (Abs).

27 Oct 2022

Updapted BA.4/5 COVID vaccines boost protection but might not surpass original formula

In a recent study posted to the bioRxiv* preprint server, researchers at Beth Israel Deaconess Medical Center assessed the immunogenicity associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) BA.5 bivalent messenger ribonucleic acid (mRNA) vaccine boosters.

27 Oct 2022

Increased Gibbs energy of binding indicates greater infectivity of SARS-CoV-2 BA.2.75

Researchers explore the thermodynamic properties of the SARS-CoV-2 Omicron subvariant BA.2.75 to understand its increased transmissibility.

27 Oct 2022

Omicron News and Research

RSV and kids: What you need to know

What is the role of cyclophilin-A in alleviating SARS-CoV-2 infections?

Effectiveness of prior infection in preventing reinfection with SARS-CoV-2 Omicron BA.2.75 sublineage

How does imprinted SARS-CoV-2 humoral immunity drive convergent Omicron evolution?

Exploring trends in SARS-CoV-2 RNA concentrations in wastewater

Exploring viral loads of SARS-CoV-2 Omicron BA.5 and BA.2 sublineages

WHO’s TAG-VE group present the most recent evidence on Omicron sublineages BQ.1 and XBB

SARS-CoV-2 Omicron BA.2 less severe than Delta and original Omicron

New research suggests booster dose of Novavax NVX-CoV2373 vaccine is effective against SARS-CoV-2 Omicron subvariants

Italian study evaluates COVID-19 reinfection risk among previously infected and vaccinated individuals

Psychosocial impact on pandemic workers in Shanghai during Omicron wave lockdown

An estimated 15% of U.S. adults infected with SARS-CoV-2 have long-COVID

New insights on antibody response against SARS-CoV-2 Omiron sublineages

First anti-SARS Cov2 monoclonal antibody candidate of SpikImm demonstrates excellent tolerance

Booster vaccination offered additional protection to residents and staff of California state prisons against SARS-CoV-2 Omicron

Study refutes the nicotinic hypothesis of SARS-CoV-2 infection mechanism

Scientists computationally restore the potency of an antibody against SARS-CoV-2 Omicron subvariants

Combination of multi-specificity and antibody avidity enhances protection against SARS-CoV-2

Updapted BA.4/5 COVID vaccines boost protection but might not surpass original formula

Increased Gibbs energy of binding indicates greater infectivity of SARS-CoV-2 BA.2.75

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News